Bleeding and spotting with the levonorgestrel 13.5 mg intrauterine system: the impact of insertion timing
- PMID: 30831104
- DOI: 10.1016/j.contraception.2019.02.004
Bleeding and spotting with the levonorgestrel 13.5 mg intrauterine system: the impact of insertion timing
Abstract
Objective: To assess the impact of early versus late menstrual cycle insertion on bleeding/spotting in the 90 days following levonorgestrel (LNG) 13.5 mg intrauterine system (IUS) insertion.
Study design: In this observational study, participants received a LNG 13.5 mg IUS and provided 90 days of bleeding/spotting data by answering the following daily text: "Have you had no flow (0), spotting (1), or bleeding (2) today?" We dichotomized insertion timing as early (days 1-7 from last menstrual period) and late (remainder of menstrual cycle) and compared bleeding/spotting between the two groups in the 90- and 30-day reference periods. We used multivariate regression methods to study associations between cycle day at insertion, parity, historical bleeding, recent hormonal contraceptive use and bleeding/spotting.
Results: In the 90-day dichotomous analysis (n=125), we found no differences in the number of days of bleeding/spotting, bleeding or spotting between the early and late insertion groups. In the 30-day dichotomous analysis (n=131), early insertion was associated with fewer days of bleeding than late insertion (5±3 vs. 7±4 days, p<.01). Recent hormonal contraceptive users experienced fewer days of bleeding than new users (5±4 vs. 7±3 days, p<.01). In the 90- and 30-day regression models, earlier insertion was associated with fewer days of bleeding (p=.02, p=.02). Recent contraceptive use was associated with fewer days of bleeding/spotting (90-day, p=.03) and fewer days of bleeding (30-day, p<.01). Nulliparity was associated with spotting (30-day, p=.04).
Conclusions: Early cycle insertion does not impact 90-day bleeding/spotting. Early cycle insertion and recent hormonal contraceptive use decrease 30-day bleeding.
Implications: The LNG 13.5 mg IUS may be inserted throughout the menstrual cycle with small differences in bleeding patterns in the 30 but not the 90 days following insertion. Shared decision making should determine timing of insertion.
Trial registration: ClinicalTrials.gov NCT03074903.
Keywords: Bleeding; Bleeding pattern; Insertion timing; Intrauterine system; Levonorgestrel intrauterine system; Spotting.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.Hum Reprod. 2015 Jul;30(7):1580-8. doi: 10.1093/humrep/dev102. Epub 2015 May 19. Hum Reprod. 2015. PMID: 25990577
-
Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial.Hum Reprod. 2018 Nov 1;33(11):2002-2009. doi: 10.1093/humrep/dey296. Hum Reprod. 2018. PMID: 30295731 Clinical Trial.
-
Tamoxifen for the prevention of unscheduled bleeding in new users of the levonorgestrel 52-mg intrauterine system: a randomized controlled trial.Contraception. 2019 Nov;100(5):391-396. doi: 10.1016/j.contraception.2019.06.009. Epub 2019 Jun 18. Contraception. 2019. PMID: 31226322 Free PMC article. Clinical Trial.
-
Menstrual bleeding and spotting with the Levonorgestrel Intrauterine System (52 mg) during the first-year after insertion: a systematic review and meta-analysis.Am J Obstet Gynecol. 2020 May;222(5):451-468.e9. doi: 10.1016/j.ajog.2019.09.044. Epub 2019 Oct 4. Am J Obstet Gynecol. 2020. PMID: 31589865
-
Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.Contraception. 1995 Nov;52(5):269-76. doi: 10.1016/0010-7824(95)00210-2. Contraception. 1995. PMID: 8585882 Review.
Cited by
-
Best practices for collecting repeated measures data using text messages.BMC Med Res Methodol. 2020 Jan 3;20(1):2. doi: 10.1186/s12874-019-0891-9. BMC Med Res Methodol. 2020. PMID: 31900108 Free PMC article. Review.
-
Discontinuation rates of intrauterine contraception due to unfavourable bleeding: a systematic review.BMC Womens Health. 2022 Mar 21;22(1):82. doi: 10.1186/s12905-022-01657-6. BMC Womens Health. 2022. PMID: 35313863 Free PMC article.
-
Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019): Implications for multipurpose prevention technology development.PLoS One. 2025 Jan 14;20(1):e0312957. doi: 10.1371/journal.pone.0312957. eCollection 2025. PLoS One. 2025. PMID: 39808648 Free PMC article. Clinical Trial.
-
Does Timing of Levonorgestrel Insertion in Women with Abnormal Uterine Bleeding Affect its Expulsion and Bleeding Pattern? A Follow-Up Study.J Obstet Gynaecol India. 2023 Apr;73(2):160-165. doi: 10.1007/s13224-022-01714-y. Epub 2022 Dec 14. J Obstet Gynaecol India. 2023. PMID: 37073234 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical